ANEUVO is at the forefront of developing innovative therapies aimed at treating chronic injuries and conditions that have been resistant to traditional pharmaceutical methods. Central to their approach is the ExaStim platform, a non-invasive neuromodulation system that has received FDA Breakthrough Device Designation for its potential in treating spinal cord injuries. This technology works by modulating the nervous system through electrical stimulation, which helps to regulate and reengage neural circuitries. By targeting both the central nervous system and the enteric nervous system, ExaStim aims to improve motor function and quality of life for patients suffering from paralysis, offering a promising alternative to surgical interventions.

The interdisciplinary team at ANEUVO comprises expert engineers, scientists, and clinicians who collaborate to advance neuromodulation therapies. Their research emphasizes the importance of understanding the nervous system's complex interactions, including the brain-gut axis, to develop effective treatment strategies. ANEUVO's commitment to innovation is reflected in their partnerships with leading organizations, focusing on enhancing patient outcomes for those affected by conditions that are not amenable to conventional treatments. Through their investigational therapies, ANEUVO seeks to provide life-enhancing improvements for individuals living with chronic injuries and diseases.

United States

ANEUVO® is a Platform and Therapy Development company focused on treating chronic injuries and conditions that have not been curable through traditional pharmaceutical approaches.

ExaStim™ is a non-invasive neuromodulation system developed by Aneuvo that has received FDA Breakthrough Device Designation for treating spinal cord injury.

ANEUVO

Company Details